Pirtobrutinib inhibits wild-type and mutant Bruton's tyrosine kinase-mediated signaling in chronic lymphocytic leukemia.

导出 OA

翻译打印收藏纠错

作者： Burcu,Aslan ^[1] ; Gorkem,Kismali ^[1] ; Lakesla R,Iles ^[2] ; Ganiraju C,Manyam ^[1] ; Mary L,Ayres ^[3] ; Lisa S,Chen ^[1] ; Mihai,Gagea ^[1] ; Maria Teresa Sabrina,Bertilaccio ^[4] ; William G,Wierda ^[1] ; Varsha,Gandhi ^[5]

作者单位： Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ^[1] Department of Biochemistry, Ankara University Faculty of Veterinary Medicine, Ankara, Turkey. ^[2] Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ^[3] Department of Veterinary Medicine and Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ^[4] Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ^[5] Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. vgandhi@mdanderson.org. ^[6] Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. vgandhi@mdanderson.org. ^[7]